Xu Haiming, Eleswarapu Satyam, Geiger Hartmut, Szczur Kathleen, Daria Deidre, Zheng Yi, Settleman Jeffrey, Srour Edward F, Williams David A, Filippi Marie-Dominique
Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Research Foundation, Cincinnati, OH 45229, USA.
Blood. 2009 Oct 22;114(17):3557-66. doi: 10.1182/blood-2009-02-205815. Epub 2009 Aug 27.
Hematopoietic stem cell (HSC) engraftment is a multistep process involving HSC homing to bone marrow, self-renewal, proliferation, and differentiation to mature blood cells. Here, we show that loss of p190-B RhoGTPase activating protein, a negative regulator of Rho GTPases, results in enhanced long-term engraftment during serial transplantation. This effect is associated with maintenance of functional HSC-enriched cells. Furthermore, loss of p190-B led to marked improvement of HSC in vivo repopulation capacity during ex vivo culture without altering proliferation and multilineage differentiation of HSC and progeny. Transcriptional analysis revealed that p190-B deficiency represses the up-regulation of p16(Ink4a) in HSCs in primary and secondary transplantation recipients, providing a possible mechanism of p190-B-mediated HSC functions. Our study defines p190-B as a critical transducer element of HSC self-renewal activity and long-term engraftment, thus suggesting that p190-B is a target for HSC-based therapies requiring maintenance of engraftment phenotype.
造血干细胞(HSC)植入是一个多步骤过程,涉及HSC归巢至骨髓、自我更新、增殖以及分化为成熟血细胞。在此,我们表明,Rho GTP酶的负调节因子p190-B RhoGTP酶激活蛋白的缺失会导致在连续移植过程中长期植入增强。这种效应与富含功能性HSC的细胞的维持有关。此外,p190-B的缺失导致在体外培养期间HSC体内再增殖能力显著提高,而不改变HSC及其子代的增殖和多谱系分化。转录分析显示,p190-B缺陷会抑制原发性和继发性移植受者HSC中p16(Ink4a)的上调,这为p190-B介导的HSC功能提供了一种可能的机制。我们的研究将p190-B定义为HSC自我更新活性和长期植入的关键转导元件,因此表明p190-B是需要维持植入表型的基于HSC的治疗的一个靶点。